Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI‐Foxn1nu mice
C Eicher, A Dewerth, B Kirchner… - Liver …, 2012 - Wiley Online Library
Background Multidrug resistance is a major reason for poor treatment results in advanced
hepatoblastoma (HB). Several alternative treatment options are currently under investigation …
hepatoblastoma (HB). Several alternative treatment options are currently under investigation …
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
L Liu, Y Cao, C Chen, X Zhang, A McNabola, D Wilkie… - Cancer research, 2006 - AACR
Angiogenesis and signaling through the RAF/mitogen-activated protein/extracellular signal-
regulated kinase (ERK) kinase (MEK)/ERK cascade have been reported to play important …
regulated kinase (ERK) kinase (MEK)/ERK cascade have been reported to play important …
Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts
C Eicher, A Dewerth, J Thomale, V Ellerkamp… - British journal of …, 2013 - nature.com
Background: Sorafenib has recently been shown to reduce tumour growth in
hepatoblastoma (HB) xenografts. The effect of a combined administration with cytostatic …
hepatoblastoma (HB) xenografts. The effect of a combined administration with cytostatic …
[PDF][PDF] Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT, and PI3K expression
CZ Zhang, XD Wang, HW Wang, Y Cai, LQ Chao - J BUON, 2015 - jbuon.com
Purpose: The purpose of this study was to determine the impact of sorafenib on
PI3K/AKT/mTOR signaling pathway and to further define its mechanism for treating …
PI3K/AKT/mTOR signaling pathway and to further define its mechanism for treating …
Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma
H Huynh, VC Ngo, HN Koong, D Poon… - Journal of cellular …, 2009 - Wiley Online Library
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …
An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular …
Z Wang, J Hu, SJ Qiu, XW Huang, Z Dai… - Expert opinion on …, 2011 - Taylor & Francis
Objective: The goal of this study is to investigate the effects of sorafenib on tumor growth,
recurrence and metastasis after curative resection of liver cancer. Research methods …
recurrence and metastasis after curative resection of liver cancer. Research methods …
Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor
NE El-Ashmawy, EG Khedr, HA El-Bahrawy… - Clinical and …, 2017 - Springer
Although sorafenib was approved as antiangiogenic agent in case of hepatocellular
carcinoma (HCC), the pathways mediating its antitumorigenic effects were not fully …
carcinoma (HCC), the pathways mediating its antitumorigenic effects were not fully …
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a particularly vascularized solid
tumor where the Raf/MEK/ERK pathway is activated; suggesting that inhibition of this …
tumor where the Raf/MEK/ERK pathway is activated; suggesting that inhibition of this …
[HTML][HTML] Synergistic antitumor effect of sorafenib in combination with ATM inhibitor in hepatocellular carcinoma cells
J Liu, Y Liu, L Meng, B Ji, D Yang - International Journal of Medical …, 2017 - ncbi.nlm.nih.gov
Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
[HTML][HTML] BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway
A Li, R Zhang, Y Zhang, X Liu, R Wang… - American Journal of …, 2019 - ncbi.nlm.nih.gov
Background: Sorafenib is an oral multi-kinase inhibitor that inhibits hepatocellular carcinoma
(HCC) via the Ras/Raf/MAPK pathway. However, sorafenib loses effectiveness because …
(HCC) via the Ras/Raf/MAPK pathway. However, sorafenib loses effectiveness because …